Listen to the most recent Podcasts developed by ESMO Open.
Surgery and HIPEC in relapse for all patients with Ovarian Cancer
Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.
Published in October 2023
ESMO Open podcast on phase II studies
ESMO Open Editor-in-Chief Professor Christoph Zielinski discusses with Dr Anna Berghoff the importance of phase II clinical trials to both the future of cancer research and the journal.
Published in November 2022
Anthracyclines for patients with early breast cancer - a debate
Dr Valentina Guarneri, of the istituto Oncologico Veneto, Padova, Italy, and Dr Evandro de Azambuja, of the Institut Jules Bordet and L’Université Libre de Bruxelles, Brussels, Belgium, discuss the pros and cons of treating patients with early breast cancer with anthracyclines.
Published in May 2022
Current highlights in lung cancer in 2021
There continues to be significant advances made in the field of lung cancer improving survival outcomes for patients. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) discusses with Prof Ben Solomon (professor in thoracic medical oncology) for his highlights on lung cancer so far in 2021.
Published in July 2021
Application of the ESMO-MCBS (V.1.1) to the field of early breast cancer therapies
The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated value scale for solid tumour anticancer treatments. Form 1 of the ESMO-MCBS, used to grade therapies with curative intent including adjuvant therapies, has only been evaluated for a limited number of studies. This is the first large-scale field testing in early breast cancer to assess the applicability of the scale to this data set and the reasonableness of derived scores and to identify any shortcomings to be addressed in future modifications of the scale.Read the full article
Published in December 2020